Cernostics, developer of AI-driven image analysis solutions for pathology assessment of tissue biopsies, announced two upcoming professional conferences at which the company will present positive clinical evidence supporting its TissueCypher® Barrett’s Esophagus Assay as a means to improve risk prediction in patients with Barrett’s esophagus in both low-grade dysplasia and non-dysplastic disease. This represents the fourth independent validation of the test. More
Client & Alumni News
Cernostics’ TissueCypher Accurately Risk Stratifies Barrett’s Esophagus Patients
The Ben Franklin Technology Partners is an initiative of the Pennsylvania Department of Community and Economic Development and is funded by the Ben Franklin Technology Development Authority.